NO2005017I2 - 1,3-Oksatiolan-nukleosidanaloger - Google Patents

1,3-Oksatiolan-nukleosidanaloger

Info

Publication number
NO2005017I2
NO2005017I2 NO2005017C NO2005017C NO2005017I2 NO 2005017 I2 NO2005017 I2 NO 2005017I2 NO 2005017 C NO2005017 C NO 2005017C NO 2005017 C NO2005017 C NO 2005017C NO 2005017 I2 NO2005017 I2 NO 2005017I2
Authority
NO
Norway
Prior art keywords
nucleoside analogues
oxathiolane nucleoside
oxathiolane
analogues
nucleoside
Prior art date
Application number
NO2005017C
Other languages
English (en)
Other versions
NO2005017I1 (no
Original Assignee
Iaf Biochem Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10699340&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2005017(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Iaf Biochem Int filed Critical Iaf Biochem Int
Publication of NO2005017I1 publication Critical patent/NO2005017I1/no
Publication of NO2005017I2 publication Critical patent/NO2005017I2/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C12P17/167—Heterorings having sulfur atoms as ring heteroatoms, e.g. vitamin B1, thiamine nucleus and open chain analogs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/38—Nucleosides
    • C12P19/40—Nucleosides having a condensed ring system containing a six-membered ring having two nitrogen atoms in the same ring, e.g. purine nucleosides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/001—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by metabolizing one of the enantiomers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/006—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by reactions involving C-N bonds, e.g. nitriles, amides, hydantoins, carbamates, lactames, transamination reactions, or keto group formation from racemic mixtures

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
NO2005017C 1991-08-01 2005-08-19 1,3-Oksatiolan-nukleosidanaloger NO2005017I2 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919116601A GB9116601D0 (en) 1991-08-01 1991-08-01 1,3-oxathiolane nucleoside analogues
PCT/CA1992/000321 WO1993003027A1 (en) 1991-08-01 1992-07-24 1,3-oxathiolane nucleoside analogues

Publications (2)

Publication Number Publication Date
NO2005017I1 NO2005017I1 (no) 2005-09-05
NO2005017I2 true NO2005017I2 (no) 2007-10-01

Family

ID=10699340

Family Applications (3)

Application Number Title Priority Date Filing Date
NO940322A NO300842B1 (no) 1991-08-01 1994-01-31 1,3-oksatiolan-nukleosidanaloger
NO2005017C NO2005017I2 (no) 1991-08-01 2005-08-19 1,3-Oksatiolan-nukleosidanaloger
NO2008009C NO2008009I1 (no) 1991-08-01 2008-06-12 Emtricitabine i kombinasjon med tenofovir disproksil, spesielt fumaratet derav, samt efavirenz

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO940322A NO300842B1 (no) 1991-08-01 1994-01-31 1,3-oksatiolan-nukleosidanaloger

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2008009C NO2008009I1 (no) 1991-08-01 2008-06-12 Emtricitabine i kombinasjon med tenofovir disproksil, spesielt fumaratet derav, samt efavirenz

Country Status (41)

Country Link
US (2) US5538975A (no)
EP (2) EP0526253B1 (no)
JP (1) JP2960778B2 (no)
KR (1) KR100242454B1 (no)
CN (5) CN101066970A (no)
AP (1) AP321A (no)
AT (2) ATE448787T1 (no)
AU (1) AU659668B2 (no)
BG (1) BG61693B1 (no)
CA (2) CA2114221C (no)
CZ (1) CZ283765B6 (no)
DE (2) DE69233776D1 (no)
DK (2) DK0526253T3 (no)
EE (1) EE03002B1 (no)
EG (1) EG20193A (no)
ES (2) ES2186667T3 (no)
FI (1) FI940435A (no)
GB (1) GB9116601D0 (no)
GE (1) GEP20002094B (no)
HK (2) HK1008672A1 (no)
HN (1) HN1997000118A (no)
HU (2) HUT70030A (no)
IL (1) IL102616A (no)
MA (1) MA22919A1 (no)
MD (1) MD1434C2 (no)
MX (1) MX9204474A (no)
NO (3) NO300842B1 (no)
NZ (1) NZ243637A (no)
OA (1) OA09883A (no)
PH (1) PH30983A (no)
PT (2) PT526253E (no)
RS (1) RS49993B (no)
RU (1) RU2126405C1 (no)
SG (1) SG68541A1 (no)
SK (1) SK280131B6 (no)
TJ (1) TJ244R3 (no)
TN (1) TNSN92070A1 (no)
TW (2) TW366347B (no)
WO (1) WO1993003027A1 (no)
YU (1) YU49259B (no)
ZA (1) ZA925668B (no)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903224B2 (en) 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6642245B1 (en) * 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US6069252A (en) * 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US6812233B1 (en) * 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
GB9226927D0 (en) * 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
GB9311709D0 (en) * 1993-06-07 1993-07-21 Iaf Biochem Int Stereoselective synthesis of nucleoside analogues using bicycle intermediate
AU7954694A (en) * 1993-09-10 1995-03-27 Centre National De La Recherche Scientifique (Cnrs) Nucleosides with anti-hepatitis b virus activity
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL113432A (en) * 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
GB9506644D0 (en) * 1995-03-31 1995-05-24 Wellcome Found Preparation of nucleoside analogues
ES2276404T3 (es) 1995-06-07 2007-06-16 Emory University Nucleosidos con actividad antivirus de la hepatitis-b.
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
DE69823984T2 (de) * 1997-03-19 2005-05-12 University Of Georgia Research Foundation, Inc. Synthese, anti-hiv- und anti-hepatitis-b-virus-aktivitäten von 1,3-oxaselenolannukleosiden
CA2285577A1 (en) 1997-04-07 1998-10-15 Triangle Pharmaceuticals, Inc. Compositions containing mkc-442 in combination with other antiviral agents
RU2244712C2 (ru) 1998-08-12 2005-01-20 Гайлид Сайенсиз, Инк. Способ получения 1,3-оксатиоланового нуклеозида, способ получения производного 1,3-оксатиоланил-5-она
US6979561B1 (en) 1998-10-09 2005-12-27 Gilead Sciences, Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
CN1173705C (zh) 1998-11-02 2004-11-03 三角药物公司 β－2－羟甲基－5－(5－氟胞嘧啶－1－基)－1,3－噁噻戊环在制药中的应用及含有该化合物的药物组合物
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
DE60123042T2 (de) * 2000-03-29 2007-04-12 Georgetown University L-fmau zur behandlung von hepatitis-delta-virus-infizierung
CA2308559C (en) 2000-05-16 2005-07-26 Brantford Chemicals Inc. 1,3-oxathiolan-5-ones useful in the production of antiviral nucleoside analogues
AU2008202336B2 (en) * 2001-03-01 2011-11-10 Abbvie Inc. Polymorphic and other crystalline forms of cis-FTC
CN1503796B (zh) * 2001-03-01 2012-07-04 三角药品公司 顺-ftc的多晶型物及其它晶型
BR0214940A (pt) * 2001-12-14 2006-05-30 Pharmasset Ltd preparação de intermediários úteis na sìntese de nucleosìdeos antivirais
SI1583542T1 (sl) * 2003-01-14 2008-12-31 Gilead Sciences Inc Sestavki in postopki za kombinacijsko antivirusnoterapijo
ITMI20030578A1 (it) 2003-03-24 2004-09-25 Clariant Lsm Italia Spa Processo ed intermedi per la preparazione di emtricitabina
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
CN100360528C (zh) * 2005-08-31 2008-01-09 四川大学 4-氨基-1-(2-羟甲基-1,3-氧硫杂环戊烷-5-基)-2(1h)-嘧啶酮的制备方法
WO2007077505A2 (en) * 2005-12-30 2007-07-12 Ranbaxy Laboratories Limited Crystalline l-menthyl (2r, 5s)-5-(4-amino-5-fluoro-2-oxo-2h-pyrimidin-1-yl)[1, 3]oxathiolan-2-carboxylate and process for preparation thereof
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
WO2010075517A2 (en) * 2008-12-23 2010-07-01 Pharmasset, Inc. Nucleoside analogs
NZ593648A (en) * 2008-12-23 2013-09-27 Gilead Pharmasset Llc Nucleoside phosphoramidates
PA8855801A1 (es) 2008-12-23 2010-07-27 Sintesis de nucleosidos de purina
US9683226B2 (en) 2009-04-03 2017-06-20 Medical Research Council Mutants of activation-induced cytidine deaminase (AID) and methods of use
EP2377862A1 (en) 2010-03-29 2011-10-19 Esteve Química, S.A. Process for obtaining emtricitabine
ES2551944T3 (es) 2010-03-31 2015-11-24 Gilead Pharmasset Llc (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihidropirimidin-1-(2H)-il)-4-fluoro-3-hidroxi-4-metiltetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato de isopropilo cristalino
CN104254379B (zh) 2012-01-10 2017-02-22 C·C·詹森有限公司 用于清洁降解的油的方法和系统
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5668674A (en) * 1979-11-08 1981-06-09 Shionogi & Co Ltd 5-fluorouracil derivative
DE2950317A1 (de) * 1979-12-14 1981-06-19 Agfa-Gevaert Ag, 5090 Leverkusen Elektrothermographische vorrichtung
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5270315A (en) * 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
ES2196004T3 (es) * 1989-02-08 2003-12-16 Iaf Biochem Int Procedimiento para preparar 1,3-oxatiolanos sustituidos con propiedades antivirales.
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
AU9125991A (en) * 1990-12-05 1992-07-08 University Of Georgia Research Foundation, Inc., The Enantiomerically pure beta -l-(-)-1,3-oxathiolane nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
NZ250842A (en) * 1991-02-22 1996-03-26 Univ Emory Resolution of a racemic mixture of nucleoside enantiomers such as 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (ftc)
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
ES2286072T3 (es) * 1991-03-06 2007-12-01 Emory University Sales de amidas de (-)cis 5 fluoro-2'-dedoxi-3'-tiacitidina utiles para el tratamiento de la hepatitis b.
WO1992018517A1 (en) * 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues

Also Published As

Publication number Publication date
NZ243637A (en) 1995-03-28
CN1070191A (zh) 1993-03-24
IL102616A (en) 1996-10-31
HK1038189A1 (en) 2002-03-08
AP9200414A0 (en) 1992-07-31
EP0526253B1 (en) 2002-11-13
DE69232845D1 (de) 2002-12-19
GB9116601D0 (en) 1991-09-18
EP1155695A1 (en) 2001-11-21
CN101066970A (zh) 2007-11-07
CN100542535C (zh) 2009-09-23
ATE227720T1 (de) 2002-11-15
PT526253E (pt) 2003-03-31
RS49993B (sr) 2008-09-29
EG20193A (en) 1997-10-30
DK1155695T3 (da) 2010-04-06
HK1008672A1 (en) 1999-05-14
DE69233776D1 (de) 2009-12-31
CZ20394A3 (en) 1994-07-13
BG61693B1 (bg) 1998-03-31
ES2335968T3 (es) 2010-04-07
MD950114A (en) 1996-06-28
YU74992A (sh) 1995-12-04
TW366347B (en) 1999-08-11
EE03002B1 (et) 1997-06-16
NO2008009I1 (no) 2008-06-30
SK10494A3 (en) 1994-12-07
TWI232217B (en) 2005-05-11
CZ283765B6 (cs) 1998-06-17
DE69232845T2 (de) 2003-04-24
NO940322D0 (no) 1994-01-31
ZA925668B (en) 1993-04-28
MD1434B2 (en) 2000-03-31
CA2682254A1 (en) 1993-02-18
NO300842B1 (no) 1997-08-04
ES2186667T3 (es) 2003-05-16
YU72303A (sh) 2006-05-25
KR100242454B1 (ko) 2000-03-02
CN101074228A (zh) 2007-11-21
CN1302612A (zh) 2001-07-11
PH30983A (en) 1997-12-23
PT1155695E (pt) 2010-02-02
IL102616A0 (en) 1993-01-14
JP2960778B2 (ja) 1999-10-12
CN1132073A (zh) 1996-10-02
FI940435A0 (fi) 1994-01-28
EP1155695B1 (en) 2009-11-18
CA2114221A1 (en) 1993-02-18
HN1997000118A (es) 1999-11-12
AU2340892A (en) 1993-03-02
NO940322L (no) 1994-03-21
EP0526253A1 (en) 1993-02-03
CA2114221C (en) 2009-12-22
BG98616A (bg) 1995-03-31
GEP20002094B (en) 2000-05-10
DK0526253T3 (da) 2003-03-17
YU49259B (sh) 2004-12-31
US5618820A (en) 1997-04-08
CA2682254C (en) 2012-02-21
MD1434C2 (ro) 2000-12-31
HU211333A9 (en) 1995-11-28
SK280131B6 (sk) 1999-08-06
ATE448787T1 (de) 2009-12-15
CN1034810C (zh) 1997-05-07
US5538975A (en) 1996-07-23
SG68541A1 (en) 1999-11-16
FI940435A (fi) 1994-01-28
TNSN92070A1 (fr) 1993-06-08
RU2126405C1 (ru) 1999-02-20
HU9400285D0 (en) 1994-05-30
OA09883A (en) 1994-09-15
AP321A (en) 1994-02-28
CN1074924C (zh) 2001-11-21
HUT70030A (en) 1995-09-28
MA22919A1 (fr) 1993-04-01
WO1993003027A1 (en) 1993-02-18
JPH07500317A (ja) 1995-01-12
MX9204474A (es) 1993-12-01
AU659668B2 (en) 1995-05-25
NO2005017I1 (no) 2005-09-05
TJ244R3 (en) 1999-11-24

Similar Documents

Publication Publication Date Title
NO2005017I2 (no) 1,3-Oksatiolan-nukleosidanaloger
OA09559A (fr) 1,3-oxathiolane nucleoside analogues.
NL960025I2 (nl) Gesubstitueerde 1,3-oxathiolanen met antivirale activiteit.
DK23489A (da) Nucleosidderivater
FI893948A0 (fi) Antiviral behandlingsfoerfarande.
DE68918711D1 (de) Reinigungsmittel.
NO912804D0 (no) Purinderivater.
MX9102794A (es) Analogos de carbaciclina.
DK95791A (da) Nucleosidanaloge
DE68922683D1 (de) Handwebstuhl.
BA96098A (bs) 1,3-Oksatiolanski nukleozidni analozi
FI923542A (fi) Faestanordning foer klingor, isynnerhet i bestrykningsmaskiner
NO933064D0 (no) Hetero-antracyklin-antitumor-analoger
DE68914451D1 (de) Mundversorgungsmittel.
NO911965L (no) Nukleosid-analoger.
NO934541D0 (no) LHRH analoger
FI915063A0 (fi) Friktionsorgan med en eller flera funktioner.
FI895480A (fi) Styv takkonstruktion.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application